The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) is a multi-professional organization whose aim is to promote the health of children through knowledge creation and the dissemination of science-based information. The annual meeting attracts close to 5,000 participants from all around the world, making the congress the largest conference of its kind.
Chr. Hansen is excited to be present at the physical event, in a joint collaboration between its Human Health business unit and the new HMO division focusing on human milk oligosaccharides for infant formula, bringing the recipe closer to breast milk.
Making a positive difference through cutting edge science and technology
“It is the first time since 2019 that ESPGHAN takes place physically. We very much look forward to reconnecting with health care professionals and other industry professionals and discuss our 5 HMO study and other new topics in the world of HMOs, probiotics and infant microbiome science,” says Veronika Müller-Wigger, senior manager Commercial Development, Chr. Hansen HMO.
“At Chr. Hansen, we use our science and technology to make a positive difference in the world by supporting infant health. We rely on our strongholds in terms of innovation, next level quality and safety when developing new solutions within probiotics and HMOs, and we have some of the world’s most documented strains in our portfolio,” elaborates Karoline Thorsoee Elmstroem, director, Global Marketing, Human Health.
“HMO is a new area, a natural next step for Chr. Hansen. The latest research shows that added to infant formula, HMOs, which are natural prebiotic fibers in breast milk, contribute to health benefits, such as supporting the immune system and healthy brain development. Also, HMOs are indicated to support gut maturation and resilience, as well as promotion of a balanced gut microbiome. Combined, HMOs and probiotics can have strong complementary or even synbiotic synergies,” adds Müller-Wigger.
“We are bringing our team of experts who can provide insight into the latest research generated across HMOs and probiotics for infant health. We are particularly excited to present a poster and give a brief presentation during the e-poster session on the Saturday (June 25th), and not least excited about the opportunity to engage in great discussions on infant microbiome science,” they both conclude.
Don’t miss out
- Make sure to find the Chr. Hansen stand, booth no. 7, where our team looks forward to engaging with visitors, meeting up with old friends and getting to know new ones in the exciting field of connecting the microbiome science with commercial opportunities.
We look forward to seeing you at a short ”Meet our experts” session on Friday, June 24
at 2.00 – 2.30 pm, at our booth. Here Yannik Schoenknecht, PhD, scientific advisor, HMO, and Stine Ninel Hansen, scientific advisor, Human Health will discuss the science behind our unique product offering supporting infant health.
- Don’t hesitate to reach out to us if you want to schedule a meeting with us during the event. Contact Frida Hjaltested, Marketing & Commercial Manager.
Breastfeeding is best. Chr. Hansen supports the World Health Organization (WHO) recommendation of breastfeeding exclusively for the first six months, followed by continued breastfeeding together with complementary foods.
科 汉森是一家全球性且具备差异化的生物科技公司，为食品行业、营养行业、制药行业和畜牧业开发天然原料的解决方案。 在科 汉森，我们拥有独特的优势，可通过微生物解决方案推动积极的变革。 在过去超过 145 年的时间里，我们致力于实现可持续的农业、更好的食品以及让全世界更多的人过上更健康的生活。 我们的微生物和发酵技术平台拥有改变规则的潜力，库存广泛且价值重大，包括约 40,000 种微生物菌株。 除了适应客户需求和全球趋势外，我们还将挖掘释放有益菌的力量，以应对食物浪费、全球健康以及抗生素和杀虫剂滥用等全球挑战。 作为全世界最具可持续性的生物技术公司，我们每天影响超过 10 亿人的生活。 受我们的创新传统与对前沿科学的求知驱动，公司宗旨“To grow a better world. Naturally.”体现在我们的所有工作中。